These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15757077)

  • 1. Effect of preexisting statin use on expression of C-reactive protein, adhesion molecules, interleukin-6, and antioxidized low-density lipoprotein antibody in patients with unstable angina undergoing coronary stenting.
    Doo YC; Han SJ; Han SW; Park WJ; Choi SH; Cho GY; Hong KS; Han KR; Lee NH; Oh DJ; Ryu KH; Rim CY; Lee KH; Lee Y
    Clin Cardiol; 2005 Feb; 28(2):72-6. PubMed ID: 15757077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between C-reactive protein and circulating cell adhesion molecules in patients with unstable angina undergoing coronary intervention and their clinical implication.
    Doo YC; Han SJ; Park WJ; Kim SM; Choi SH; Cho GY; Hong KS; Han KR; Lee NH; Oh DJ; Ryu KH; Rhim CY; Lee KH; Lee Y
    Clin Cardiol; 2005 Jan; 28(1):47-51. PubMed ID: 15704532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations among oxidized low-density lipoprotein antibody, C-reactive protein, interleukin-6, and circulating cell adhesion molecules in patients with unstable angina pectoris.
    Doo YC; Han SJ; Lee JH; Cho GY; Hong KS; Han KR; Lee NH; Oh DJ; Ryu KH; Rhim CY; Lee KH; Lee Y
    Am J Cardiol; 2004 Mar; 93(5):554-8. PubMed ID: 14996578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina.
    Chyrchel M; Dudek D; Bartuś S; Legutko J; Heba G; Dubiel JS
    Kardiol Pol; 2004 Sep; 61(9):213-21; discussion 222-4. PubMed ID: 15531933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-elevation of high-sensitivity C-reactive protein but not the von Willebrand Factor after withdrawing atorvastatin therapy in patients with unstable angina undergoing coronary artery stenting.
    Yip HK; Youssef AA; Chua S; Hung WC; Chen YH; Yeh KH; Wu CJ; Hang CL
    Int Heart J; 2006 Jul; 47(4):501-9. PubMed ID: 16960405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Leslie SJ; Sasiela WJ; Szarek M; Libby P; Ganz P;
    Circulation; 2003 Sep; 108(13):1560-6. PubMed ID: 12975259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules.
    Mulvihill NT; Foley JB; Murphy RT; Curtin R; Crean PA; Walsh M
    Heart; 2001 Jun; 85(6):623-7. PubMed ID: 11359739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation between soluble intercellular adhesion molecule-1, statin therapy, and long-term risk of clinical cardiovascular events in patients with previous acute coronary syndrome (from PROVE IT-TIMI 22).
    Ray KK; Morrow DA; Shui A; Rifai N; Cannon CP
    Am J Cardiol; 2006 Oct; 98(7):861-5. PubMed ID: 16996863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting.
    Hong YJ; Jeong MH; Lim SY; Lee SR; Kim KH; Sohn IS; Park HW; Kim JH; Kim W; Ahn Y; Cho JG; Park JC; Kang JC
    Circ J; 2005 Dec; 69(12):1477-83. PubMed ID: 16308495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting.
    Inoue T; Kato T; Uchida T; Sakuma M; Nakajima A; Shibazaki M; Imoto Y; Saito M; Hashimoto S; Hikichi Y; Node K
    J Am Coll Cardiol; 2005 Jul; 46(2):239-45. PubMed ID: 16022949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up.
    Hartford M; Wiklund O; Mattsson Hultén L; Perers E; Person A; Herlitz J; Hurt-Camejo E; Karlsson T; Caidahl K
    Int J Cardiol; 2006 Mar; 108(1):55-62. PubMed ID: 16516698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early release of neutrophil markers of activation after direct stenting in patients with unstable angina.
    Gach O; Biémar C; Nys M; Deby-Dupont G; Chapelle JP; Deby C; Lamy M; Piérard LA; Legrand V
    Coron Artery Dis; 2005 Feb; 16(1):59-65. PubMed ID: 15654202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibodies against oxidized low density lipoproteins in patients with stable angina, unstable angina or peripheral vascular disease; pathophysiological implications.
    Monaco C; Crea F; Niccoli G; Summaria F; Cianflone D; Bordone R; Bellomo G; Maseri A
    Eur Heart J; 2001 Sep; 22(17):1572-7. PubMed ID: 11492986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of C-reactive protein, fibrinogen, interleukin-6, and macrophage colony stimulating factor in severe unstable angina.
    Rallidis LS; Zolindaki MG; Manioudaki HS; Laoutaris NP; Velissaridou AH; Papasteriadis EG
    Clin Cardiol; 2002 Nov; 25(11):505-10. PubMed ID: 12430780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial changes in circulating concentrations of soluble CD40 ligand and C-reactive protein in patients with unstable angina undergoing coronary stenting.
    Yip HK; Wu CJ; Yang CH; Chang HW; Fang CY; Hung WC; Hang CL
    Circ J; 2005 Aug; 69(8):890-5. PubMed ID: 16041155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
    Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of statin therapy on plasma markers of inflammation in patients without vascular disease.
    Ky B; Rader DJ
    Clin Cardiol; 2005 Feb; 28(2):67-70. PubMed ID: 15757075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomized Controlled Trial.
    Takase S; Matoba T; Nakashiro S; Mukai Y; Inoue S; Oi K; Higo T; Katsuki S; Takemoto M; Suematsu N; Eshima K; Miyata K; Yamamoto M; Usui M; Sadamatsu K; Satoh S; Kadokami T; Hironaga K; Ichi I; Todaka K; Kishimoto J; Egashira K; Sunagawa K
    Arterioscler Thromb Vasc Biol; 2017 Feb; 37(2):350-358. PubMed ID: 27932353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia.
    Rosenson RS; Wolff D; Tangney CC
    Clin Sci (Lond); 2004 Feb; 106(2):215-7. PubMed ID: 12967321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different patterns of interleukin-6 and von Willebrand factor antigen changes after coronary stenting in unstable versus stable angina.
    Spaziani D; De Servi S; Morelli B; D'Urbano M; Vandoni P; Mariani G; Passoni F; Cafiero F
    Ital Heart J; 2002 Oct; 3(10):593-7. PubMed ID: 12478817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.